One type of cholesterol drug makes the body produce more of a protein called PCSK9, while another type actually reduces it — so they work in opposite ways even though they target the same thing.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

Narrative Review

2025 Apr

The study shows that one type of PCSK9 drug (antibodies) causes the body to make more PCSK9, while the other (inclisiran) reduces it, which matches the claim.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

Score: 1

DOI: 10.1016/j.pharmthera.2025.108812

Similar Assertions

Inclisiran is a type of medicine that helps lower bad cholesterol by turning down a protein in the liver. It works longer than some other cholesterol drugs, so you don’t need to take it as often.

1

0

76%

Two newer cholesterol drugs, when added to the strongest statins, can cut bad cholesterol by another half — helping high-risk patients get their levels down to what doctors recommend.

1

0

74%